Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

[1]  N. Ohuchi,et al.  Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers , 2016, Breast Cancer.

[2]  Rory Stark,et al.  Progesterone receptor modulates estrogen receptor-α action in breast cancer , 2015, Nature.

[3]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  F. André,et al.  Ki67—no evidence for its use in node-positive breast cancer , 2015, Nature Reviews Clinical Oncology.

[5]  T. Miyazaki,et al.  Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility , 2015, Journal of Clinical Pathology.

[6]  A. Luini,et al.  Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.

[7]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[8]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  H. Iwase,et al.  Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens , 2013, Breast Cancer.

[10]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Dowsett,et al.  Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Harald Frick,et al.  How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists , 2012, PloS one.

[13]  Ben Tran,et al.  Luminal-B breast cancer and novel therapeutic targets , 2011, Breast Cancer Research.

[14]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[15]  T. Osako,et al.  Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis , 2010, Breast cancer.

[16]  S. Hayashi,et al.  Estrogen signaling pathway and hormonal therapy , 2008, Breast cancer.

[17]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[18]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[19]  Christopher J. Barnes,et al.  The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Mitch Dowsett,et al.  Aromatase inhibitors for breast cancer: lessons from the laboratory , 2003, Nature Reviews Cancer.

[21]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Molinolo,et al.  Progesterone receptors - animal models and cell signalling in breast cancer: Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer , 2002, Breast Cancer Research.

[24]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[25]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[27]  Takuji Iwase,et al.  Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy , 2013, Breast Cancer.

[28]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.